Tanga Medical Research Centre
Tanga Medical Research Centre (NIMR-Tanga) is one of the eight (8) centres of NIMR. The Centre had been operating as a Research Field Station known as Bombo (formerly Filariasis Research Centre under WHO) under the NIMR Amani Centre until August 2005 when the Centre became fully operational as NIMR Tanga Centre. Thereafter, most of the clinical research activities were shifted from Amani Hills in Muheza District to Tanga City. The Centre is situated next to Tanga Regional Referral Hospital in Tanga and has two sister Laboratories named Amani Biomedical Research Laboratory (AMBRELA) in Tanga and NIMR Korogwe Research Laboratory next to Korogwe District Hospital in Korogwe, Tanga.
The Centre represents a unique and high-quality research platform with all the necessary scientific expertise underpinned by the combination of excellent laboratory facilities, compliance with the local regulations, and the international Good Clinical Practice Standards (ICH-GCP) and access to a well-defined field population that is key in executing a wide array of clinical and biomedical research. The centre works in line with the National health priorities as well NIMR strategic plans. We conduct multidisciplinary research, extending from Biomedical Sciences (parasitology, immunology, biochemistry and molecular biology as well as virology and microbiology) through clinical research to epidemiology and public health at large. The Centre is at the forefront of resolving important research questions in health and delivering effective translation of scientific evidence into patient care, disease prevention, control and elimination. More importantly is the provision of evidence-based data that are important in assisting policy decision makers in setting up national guidelines for managing various disease problems across the country and beyond.
CLINICAL TRIAL FACILITIES
Tanga Centre conducts clinical research across a wider range of therapeutic areas on diseases of local and global public health importance. The Centre has two clinical trial Units (CTU) in Tanga City and Korogwe District that have all the key facilities to support patient recruitment, rigorous ethical ®ulatory process, monitoring, clinical trial management, statistical plan, analysis and reporting, data management, pharmacy services, community engagement and IT systems. Our research focus include the diagnostics, prevention and treatment, pharmacovigilance research with emphasis on malaria, HIV and Co-morbidities, neglected tropical diseases (NTDs), non-communicable diseases (NCDs) and emerging/reemerging infectious diseases including COVID-19 and other viral diseases. The CTU team has excellent expertise in ICH-GCP Standards, clinical trials management and monitoring, clinical data management and biostatistics for conducting clinical trials (Phase I-IV). The CTU services support both academic and investigator-initiated clinical studies and are also open to studies sponsored by the industry. We consider clinical trials which are of high quality, methodologically and medically sound which address relevant health issues. The Centre has excellent specimen repositories and both paper based and electronic based data archiving facilities.
The Centre two modern research laboratories and training with facilities at Tanga and Korogwe. The laboratories have conventional PCR machines, modern quantitative real-time PCR (qPCR) with high resolution melting capability, gel documentation system for molecular analysis , High-performance liquid chromatography (HPLC) machine ,ELISA readers , Roche Cobas c 111 biochemical analysers, facilities for cell culture, Flow cytometer (FACS Calibur) for cell Mediated Immunological Assays, Haematological analyzers, BACTEC machines for Blood culture, ROCHE Cobas AmpliPrep/Cobas TaqMan (CAP/CTM 96) for HIV-1 viral load (HVL) and early infant diagnosis (EID) assays , light and automated microscopes, pharmacy facilities. Sample storage facilities include -20°C, -40°C and -80°C freezers, and -°121 C liquid nitrogen facilities for cryopreservation. The laboratories also have class II laminar flow hoods for asceptic preparation of cells for cell culture and purification. Others include high-speed internet connection via fibre optic, tablets for field data collection, fully equipped data management and statistics unit including Open Data Kit (ODK) server and high-performing standby generators
CLINICAL TRIAL EXPERIENCE
- Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania (InSMART-school), ClinicalTrials.gov Identifier: NCT03640403, Sponsor, University of Antwerp, Belgium.
- Efficacy and safety of artemisinin-based combination treatments (ACTs) for the treatment of uncomplicated Plasmodium falciparum malaria across sentinel sites in Tanzania (programmatic trials to support MoH/NMCP)
- Improving PRegnancy Outcomes with Intermittent preVEntive Treatment in Africa (IMPROVE), ClinicalTrials.gov Identifier: NCT03208179, Sponsor: Liverpool School of Tropical Medicine, UK.
- Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to Falciparum Infection in Children. Sponsor: GlaxoSmithKline, ClinicalTrials.gov Identifier: NCT00380393,
- Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals’ Candidate Malaria Vaccine in Infants and Children in Africa, Sponsor: GlaxoSmithKline gov Identifier: NCT02207816
- Phase Ib Trial of MSP3 LSP in Children in Tanzania (MSP3TN), Sponsor: African Malaria Network Trust, ClinicalTrials.gov Identifier: NCT00469651,
- Backup with Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT), Sponsor: Rigshospitalet, Denmark, ClinicalTrials.gov Identifier: NCT00346567
- Africa Quinine versus Artesunate in Severe Malaria Trial (AQUAMAT TRIAL), registration Number ISRCTN50258054
- A double-blind, randomised, placebo-controlled field trial of doxycycline for individuals infected with bancrofti in Tanzania
National Malaria Control Programme (NMCP), Tanga Regional Referral Hospital, Kilimanjaro Christian Medical Center (KCMC), Kilimanjaro Clinical Research Institute (KCRI), Kenya Medical Research Institute (KEMRI), Tanga International Conference Competency Centre (TICC) , Catholic University of Health and Allied Sciences (CUHAS), Muhimbili University of Health and Allied Sciences(MUHAS), Bonn University, Bernhard Nocht Institute for Tropical Medicine (BNITM), Germany, London School of Hygiene & Tropical Medicine (LSHTM), Liverpool School of Tropical Medicine(LSTM)-UK, Oxford University UK, Centre for Medical Parasitology, University of Copenhagen-Denmark, Global Health Institute (GHI)-University of Antwerp, Belgium, Bjorknes University College, Oslo, Norway, European & Developing Countries Clinical Trials Partnership (EDCTP), DANIDA, EU, WHO, VLIR-UOS, Belgium, PATH Malaria Vaccine Initiative (MVI), GlaxoSmithKline (GSK), Belgium, Lund University, Sweden, Novartis Pharmaceuticals, Switzerland, United States Agency for International Development (USAID), President’s Malaria Initiative (PMI), University of North Carolina and Harvard T.H Chan School of Public Health, Centers for Disease Control and Prevention (CDC), USA.